Patent Assignment
Reel/Frame 061152/0251
Assignment of Assignor's Interest
Recorded: 2022-09-20
Pages: 8
Assignors
LANGRISH, CLAIRE
Executed: 2022-07-13
NUNN, PHILIP
Executed: 2022-09-08
THOMAS, DOLCA
Executed: 2022-07-12
Assignee
PRINCIPIA BIOPHARMA INC.
220 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CALIFORNIA, 94080
Covered Properties
(3)
TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONY]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERIZIN-1-YL]PENT-2-ENENITRILE
Application:
62/957,724 →
TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONY]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERIZIN-1-YL]PENT-2-ENENITRILE
Application:
63/039,200 →
TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
Related Assignments
(1)
Other recorded transfers of the patents in this record — the chain of ownership.